233 studies found for:    "Adenocarcinoma of lung"
Show Display Options
Rank Status Study
21 Active, not recruiting
Has Results
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: paclitaxel;   Drug: carboplatin
22 Recruiting Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases
Conditions: Non-small Cell Lung Cancer Metastatic;   Non Epidermoid;   Non-small Cell Lung Cancer;   Adenocarcinoma of Lung Metastatic to Brain;   Cerebral Metastases;   Cerebral Radiotherapy;   Brain Radiotherapy;   Bevacizumab
Interventions: Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Bevacizumab;   Radiation: Cerebral Radiotherapy
23 Recruiting A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Conditions: Non-Small-Cell Lung Adenocarcinoma;   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Arm A: single agent docetaxel;   Drug: Arm B: Combination of ganetespib and docetaxel
24 Completed Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: sorafenib
25 Recruiting Neoadjuvant Pemetrexed, Cisplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: Neoadjuvant Bevacizumab
26 Active, not recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Condition: Cancer
Intervention: Drug: SNX-5422
27 Recruiting A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Dietary Supplement: Silybin-phytosome
28 Recruiting Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Conditions: Non Small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Gefitinib;   Drug: Placebo;   Drug: Pemetrexed plusCIsplatin
29 Completed First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
Condition: Lung Cancer
Interventions: Drug: Gefitinib;   Procedure: chemotherapy
30 Recruiting Whole-Exome Sequencing (WES) of Cancer Patients
Conditions: Lung Adenocarcinoma;   Colon Adenocarcinoma
Intervention:
31 Recruiting PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: PI3K inhibitor BKM120;   Drug: pemetrexed disodium;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: quality-of-life assessment
32 Active, not recruiting Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
33 Active, not recruiting MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
34 Completed Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Drug: docetaxel;   Drug: etoposide;   Drug: gefitinib;   Radiation: radiation therapy;   Other: placebo
35 Completed S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
36 Not yet recruiting Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
Conditions: Adenocarcinoma of the Lung;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: crizotinib;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
37 Active, not recruiting Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Drug: etoposide;   Radiation: radiation therapy;   Biological: bevacizumab;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim
38 Active, not recruiting Photodynamic Therapy in Treating Patients With Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage 0 Non-small Cell Lung Cancer
Interventions: Drug: HPPH;   Drug: photodynamic therapy;   Procedure: therapeutic bronchoscopy
39 Recruiting Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: external beam radiation therapy;   Radiation: image-guided adaptive radiation therapy;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
40 Terminated Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Drug: etoposide;   Drug: erlotinib hydrochloride;   Radiation: radiation therapy;   Drug: docetaxel;   Drug: paclitaxel;   Drug: carboplatin;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years